Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Addex Therapeutics Ltd
  6. News
  7. Summary
    ADXN   CH0029850754

ADDEX THERAPEUTICS LTD

(ADXN)
  Report
Delayed Swiss Exchange  -  11:31 2022-11-25 am EST
0.1350 CHF   -3.57%
11/14Addex Therapeutics : INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Form 6-K
PU
11/11Transcript : Addex Therapeutics Ltd, Q3 2022 Earnings Call, Nov 11, 2022
CI
11/11Addex Therapeutics Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Addex to Present at the Sachs Associates 22nd Annual Biotech in Europe Forum & Baader Investment Conference

09/20/2022 | 01:00am EST

Geneva, Switzerland, September 20, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer will present at both the Sachs Associates 22nd Annual Biotech in Europe forum in Basel, Switzerland and the Baader Investment Conference in Munich, Germany taking place September 21 - 22, 2022 and September 23, 2022, respectively.

In his presentations, Mr. Dyer will provide a corporate update and discuss recent developments at Addex. A video of each presentation will be available for viewing on-demand by registered participants.

Mr. Dyer will also participate in a neurodegenerative diseases roundtable discussion with other panelists at the Sachs Associates Conference, scheduled on September 22, 2022.

Mr. Dyer will be available for one-on-one meetings throughout both conferences. For more information or to schedule a one-on-one meeting, please contact IR@addexpharma.com.

About Addex Therapeutics:
Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available, small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional, non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention. Addex's lead drug candidate, ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration with Janssen Pharmaceuticals, Inc., is in a Phase 2a proof of concept clinical trial for the treatment of epilepsy. Addex's second clinical program, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in a range of indications. Indivior PLC has licensed Addex’s GABAB PAM program for the development of drug candidates, with a focus on substance use disorder. Addex is also advancing a broad preclinical pipeline, which includes development of a range of GABAB PAMs for CMT1A, chronic cough and several types of pain, mGlu7 NAM for stress related disorders, mGlu2 NAM for mild neurocognitive disorders and depression, M4 PAM for schizophrenia and other forms of psychosis, as well as mGlu4 PAM and mGlu3 PAM. Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol "ADXN" on each exchange.

Press Contacts:

Tim Dyer
Chief Executive Officer
Telephone: +41 22 884 15 55
PR@addextherapeutics.com
Mike Sinclair
Partner, Halsin Partners
+44 (0)7968 022075
msinclair@halsin.com

Forward Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including the ability to discover molecules as part of the Indivior collaboration, the progress of clinical trials and preclinical studies, including the timing of data read-outs from the ADX71149 epilepsy study, and our intended strategic direction. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, such as receipt of ongoing research payments and timing of the collaboration conclusion, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Addex Therapeutics’ Annual Report on Form 20-F for the year ended December 31, 2021, as filed with the SEC on March 10, 2022, the prospectus supplement and accompanying prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements.

 


© OMX, source GlobeNewswire - EU Press Releases

All news about ADDEX THERAPEUTICS LTD
11/14Addex Therapeutics : INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENT..
PU
11/11Transcript : Addex Therapeutics Ltd, Q3 2022 Earnings Call, Nov 11, 2022
CI
11/11Addex Therapeutics Ltd Reports Earnings Results for the Third Quarter and Nine Months E..
CI
11/11Addex Therapeutics' Q3 Net Loss Widens Amid Higher Operating Expenses
MT
11/11Addex Reports Q3 2022 Financial Results and Provides Corporate Update
GL
11/11Addex Reports Q3 2022 Financial Results and Provides Corporate Update
DJ
11/03Addex Flagged For Non-compliance With Nasdaq's Minimum Bid Price Rule
MT
11/03Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
GL
11/03Addex Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference C..
GL
11/03Addex Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference C..
AQ
More news
Analyst Recommendations on ADDEX THERAPEUTICS LTD
More recommendations
Financials
Sales 2022 0,95 M 1,01 M 1,01 M
Net income 2022 -17,5 M -18,4 M -18,4 M
Net cash 2022 4,63 M 4,89 M 4,89 M
P/E ratio 2022 -0,33x
Yield 2022 -
Capitalization 13,9 M 14,7 M 14,7 M
EV / Sales 2022 9,77x
EV / Sales 2023 14,7x
Nbr of Employees 26
Free-Float 71,0%
Chart ADDEX THERAPEUTICS LTD
Duration : Period :
Addex Therapeutics Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADDEX THERAPEUTICS LTD
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Last Close Price 0,14 CHF
Average target price 0,16 CHF
Spread / Average Target 18,5%
EPS Revisions
Managers and Directors
Timothy Dyer Chief Executive Officer
LÚnaic TeyssÚdou Head-Finance
Vincent M. Lawton Chairman
Roger G. Mills Director & Chief Medical Officer
Jake R. Nunn Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ADDEX THERAPEUTICS LTD-87.02%15
MODERNA, INC.-30.55%67 769
IQVIA HOLDINGS INC.-22.03%40 859
LONZA GROUP AG-33.93%39 445
ALNYLAM PHARMACEUTICALS, INC.25.44%26 171
SEAGEN INC.-20.16%22 918